June 4, 2025

Germitec announces the commercial launch of Chronos® Max

Germitec, a French MedTech company specializing in UV-C High-Level Disinfection (HLD) solutions for ultrasound probes, announces the commercial launch of Chronos® Max, designed for Cardiology and ENT departments. This next-generation HLD system for TEE (Transesophageal Echocardiography) probes and ENT endoscopes without operating channel has received CE certification under the MDR 2017/745 regulation and is classified as a Class IIb medical device.

‍

Chronos® Max will debut at the SF2H Annual Congress (French Society for Hospital Hygiene), taking place in Marseille (France), from June 4th to 6th, 2025 (Booth: 3).

‍

Chronos® Max - Crédit photo Germitec®
Chronos® Max - Photo credit: Germitec®

‍
Revolution in High-Level Disinfection: Chronos® Max combines speed, safety and efficacy

‍

Engineered to address TEE probes and ENT endoscopes without operating channel current disinfection challenges, Chronos® Max completes a disinfection cycle in about 4 minutes1. New generation of the Antigermix® system, it perpetuates Germitec’s legacy of reliability and performance.

‍

A 2-in-1 configuration has been designed to suit both Cardiology and ENT use and the larger chamber offers an end-to-end disinfection from the probe or endoscope’s active part to the connector and cable. This patented UV-C technology meets rigorous HLD standards and has demonstrated efficacy—validated by an independent laboratory—against a wide range of pathogens: bacteria, fungi, viruses (including HPV and HIV), mycobacteria and spores.

‍

Chronos® Max has been proven to inactivate the highly transmissible2,3 and resistant human papillomavirus (HPV) — responsible among others, for oropharyngeal cancer4,5,6 , and is also effective against Staphylococci (S. aureus) and Enterococci, responsible for infectious endocarditis.

‍

User-oriented ergonomics have been developed to offer intuitive handling: disinfection cycles are launched thanks to a single button and the chamber's door is equipped with a hands-free foot pedal. The technology guarantees full traceability through:

‍

  • Probe or endoscope detection within the chamber
  • Operator badge identification
  • Integrated printer for traceability labels
  • Secure connection to Germitrac® (embedded software providing access to traceability data)

‍

“With Chronos® Max, we reshaped the user experience and fine-tuned every detail to meet healthcare professionals' needs, while taking key environmental aspects into account. Our mission remains the same: to deliver a reliable, intuitive and sustainable solution that enhances patient and medical staff safety.” — Vincent Gardès, CEO of Germitec

‍

CE MDR Certification: a high-level European approval

Chronos® Max received CE certification7 under MDR 2017/745 in May 2025, confirming its compliance with the EU regulation on invasive medical devices (Rule 16, Annex VIII). This certification ensures the device meets stringent standards in terms of safety, performance, clinical evaluation and traceability.

Granted by the notified body GMED, the CE MDR certification reflects an extensive quality assurance process, including:

  • Evaluation of the quality management system in accordance with Article 10 of the MDR,
  • Detailed review of the technical documentation,
  • Rigorous clinical assessment,
  • Registration in the EUDAMED database for traceability,
  • Appointment of a Person Responsible for Regulatory Compliance (PRRC),
  • Implementation of a Post-Market Surveillance (PMS) and vigilance system.

‍

“Following Chronos® device CE MDR approval, we’re proud to see Chronos® Max reach this milestone. It reflects our team's unwavering commitment and hard work.” — Vincent Gardès, CEO of Germitec.

‍

Ambitious expansion strategy in Europe and beyond

With a commercial launch in Europe planned in June 2025, Chronos® Max represents a new milestone in Germitec’s growth strategy. Regulatory proceedings are underway in the UK and Australia, with FDA clearance expected in 2026 as part of the company’s expansion in the U.S.

‍

With CE MDR certifications for both Chronos® and Chronos® Max, Germitec reaffirms its commitment to delivering innovative, safe and efficient High-Level Disinfection solutions across Gynecology & IVF, Cardiology, Urology, ENT, Radiology, Emergency Medicine and Anesthesiology. The company is dedicated to supporting worldwide healthcare facilities in preventing Healthcare-Associated Infections (HAIs).

‍

‍

Key Figures

  • Available in over 40 countries
  • More than 2.2 million patients protected
  • Over 2,500 devices installed worldwide
  • UV-C solutions used in Gynecology & IVF | Cardiology | Urology | ENT | Radiology | Emergency Medicine | Anesthesiology | Biopsy
  • €29M Series B funding round in February 2025
  • FDA De Novo clearance for Chronos® on August 28, 2024, authorizing U.S. commercialization
  • €25M financing from the European Investment Bank (EIB) in November 2023
  • €11M raised in 2022
  • Winner of the Galien Award France 2020 for the Chronos® system

‍

About Germitec

Germitec is a French MedTech company specializing in the development and manufacturing of advanced UV-C High-Level Disinfection solutions for ultrasound probes. Its innovative products aim to reduce cross-contamination, improve workflow efficiency and ensure patients and healthcare professionals safety. Germitec is committed to delivering reliable, sustainable and effective solutions that meet the highest standard of care. 

‍

For more information, visit www.germitec.com 

‍

Press contact – Madame de la Com’ : 

Ophélie Moreau – ophelie@madamedelacom.com – +33 (0)6 32 50 77 30


1. Internal data : cycle duration subject to reaching the pre-defined UV-C dose validating the HLD cycle.

2. Meyers C, et al. (2017) UVC Radiation as an Effective Disinfectant Method to Inactivate Human Papillomavirus PLoS ONE 12 (10) : e0187377.

3. Pichon M, et al. (2019) Decontamination of Intravaginal Probes Infected by Human Papillomavirus (HPV) Using UV-C Decontamination System. J. Clin. Med, 8, 1776 ; doi:10.3390/jcm8111776.

4. Les traitements des cancers des voies aérodigestives supérieures, collection Guides patients Cancer info, INCa, décembre 2018.

5. Cancers des voies aérodigestives supérieures. Outils pour la pratique. Du diagnostic au suivi. Février 2018.

6. Barsouk A et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11:42.7.

7. MDR 2017/745 is the new regulation on medical devices that replaces the previous Medical Device Directive (MDD 93/42/EEC) in Europe.

‍